Last Updated : March 25, 2025
Details
Generic Name:
pembrolizumab
Project Status:
Received
Therapeutic Area:
Cervical cancer
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0411-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Pembrolizumab for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | February 10, 2025 |
|---|---|
| Call for patient/clinician input closed | April 07, 2025 |
| Submission received | March 25, 2025 |
| Submission accepted | - |
Last Updated : March 25, 2025